News
Biovica strengthens its commercial leadership
Uppsala, Sweden, March 25, 2020. Biovica, active in cancer diagnostics, today announced that Robert Dann is joining the organization as SVP Marketing and US Business and will be part of the management team. The appointment marks a significant milestone in the upcoming commercialization of DiviTum® on the US market.
Positive results from Swedish study with DiviTum in metastatic breast cancer published in prestigious journal
Uppsala, Sweden, March 12, 2020. Biovica, active in cancer diagnostics, today announced that results from a study by researchers at Lund University have been published in the well renowned journal Scientific Reports, a journal from Nature. The results support that the blood test DiviTum can be used as a prognostic tool for evaluating treatment outcomes in metastatic breast cancer.
DiviTum – first study published on CDK4/6 inhibitor against clinical results
Period: May-January 2019/2020
Biovica provides updates on FDA application
Uppsala, Sweden, March 10, 2020. Biovica, active in cancer diagnostics, today announced that the company intends to submit an FDA application for market approval of DiviTum in the third quarter of 2020 and not as previously announced in mid-2020.
Clinical Cancer Research publishes results supporting DiviTum as a technology for early evaluation of metastatic breast cancer treatment
Biovica, active in cancer diagnostics, today announced that the scientific journal Clinical Cancer Research has published data from the TREnd study, demonstrating the benefits of using DiviTum® when evaluating palbociclib treatment outcome in women with metastatic breast cancer.
Biovica strengthens management team
Biovica, active in cancer diagnostics, today announced that Henrik Winther was appointed SVP Business Development and will be part of the management team. He most recently comes from the role of SVP Precision Diagnostics at Immunovia.
Q2 Interim report: Work with the FDA application progressing as planned
“The results from two additional studies with DiviTum® will be presented at San Antonio Breast Cancer Symposium, the world’s largest scientific conference on breast cancer”. – Anders Rylander, CEO of Biovica
Biovica’s DiviTum – Strong prognostic marker in operable breast cancer
Uppsala, Sweden, November 20, 2019. Biovica, active in cancer biomarkers, today announced clinical data that demonstrate DiviTum as a strong prognostic marker in operable breast cancer. The results will be presented at the San Antonio Breast Cancer Symposium, SABCS, December 10-14, 2019, the world ́s largest scientific congress focusing on breast cancer.
Biovica’s DiviTum validated as a dynamic biomarker in metastatic breast cancer in collaboration with Institut Curie, Paris
Uppsala, Sweden, November 20, 2019. Biovica, active in cancer biomarkers, today announced that clinical data – demonstrating that DiviTum can be used as a dynamic, non-invasive biomarker for metastatic breast cancer patients treated with endocrine therapy and palbociclib – will be presented at the San Antonio Breast Cancer Symposium, December 10-14, 2019, the world ́s largest scientific congress focusing on breast cancer.
Biovica strengthens with new R&D Director
Uppsala, November 15, 2019. Biovica, active in cancer diagnostics, today announced that Otti Bengtsson Gref has been appointed new R&D Director and will be part of the management team. She most recently comes from the role as R&D Director at Cavidi.